Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Our AI scores Sndl Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Sndl Inc. is a small-cap company with a market capitalization of $355M. It ranks number 5 by market capitalization among the 28 Medicinal Chemicals & Botanical Products issuers in our coverage with a current forecast.
For SNDL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -21.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 4.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, SNDL included.
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Medicinal Chemicals & Botanical Products peers listed below that report each metric. Statement values were filed in CAD and are shown converted to USD (flows at the trailing twelve-month average rate, balances at the balance-sheet date rate).
| Metric | SNDL | Rank |
|---|---|---|
| Market Cap | $355M | 5/28 |
| Revenue/Share | $7.90 | – |
| FCF/Share | $0.06 | – |
| Metric | SNDL | Rank |
|---|---|---|
| ROE | -47.1% | 13/15 |
| ROA | -38.8% | 17/21 |
| ROIC | -36.9% | 16/18 |
| Gross Margin | 22.5% | 18/21 |
| Operating Margin | -16.2% | 14/23 |
| Net Margin | -18.3% | 12/19 |
| EBT Margin | -17.6% | 15/23 |
| Metric | SNDL | Rank |
|---|---|---|
| Current Ratio | 4.88x | 5/25 |
| Quick Ratio | 3.50x | 4/23 |
| D/E Ratio | 0.21x | 14/16 |
| Financial Leverage | 1.21x | 14/16 |
| Working Capital | $260M | 5/25 |
| Metric | SNDL | Rank |
|---|---|---|
| Operating Cash Flow | $37M | 3/27 |
| Free Cash Flow | $14M | 5/12 |
| Capital Spending | -$23M | 10/12 |
| FCF/Sales | 0.7% | 8/12 |
| CapEx/Sales | 1.1% | 9/12 |
| Metric | SNDL | Rank |
|---|---|---|
| Asset Turnover | 2.12x | 2/15 |
| Fixed Assets Turnover | 18.7x | 5/16 |
| Metric | SNDL | Rank |
|---|---|---|
| Total Revenue | $2.03B | 1/17 |
| Operating Income | -$328M | 26/26 |
| Net Income | -$372M | 20/21 |
| R&D Expense | $1M | 6/8 |
| Metric | SNDL | Rank |
|---|---|---|
| Shares Outstanding | 258M | – |
| Total Current Assets | $328M | 33.7% of assets |
| Cash & Short-term Investments | $184M | 18.9% of assets |
| Inventory | $92M | 9.5% of assets |
| Total Liabilities | $171M | 17.6% of assets |
Companies classified under the same SEC industry code as Sndl Inc. (Medicinal Chemicals & Botanical Products): 30 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| SNDL Sndl Inc. | $355M | |
| DFTX Definium Therapeutics, Inc. | $4.47B | |
| TRLV Trulieve Cannabis Corp. | $1.97B | |
| CRON Cronos Group Inc. | $1.33B | |
| TLRY Tilray Brands, Inc. | $432M | |
| ACB Aurora Cannabis Inc | $332M | |
| CGC Canopy Growth Corp | $276M | |
| USNA Usana Health Sciences Inc | $256M | |
| GLAS Glass House Brands Inc. | $196M | |
| MDWD Mediwound Ltd. | $171M | |
| NAGE Niagen Bioscience, Inc. | $164M | |
| AAWH Ascend Wellness Holdings, Inc. | $75M | |
| FTLF Fitlife Brands, Inc. | $75M | |
| CHUC Charlie's Holdings, Inc. | $31M | |
| BTMD Biote Corp. | $30M | |
| MRMD Marimed Inc. | $26M | |
| HYEX Healthy Extracts Inc. | $21M | |
| MTEX Mannatech Inc | $16M | |
| ADIA Adia Med, Inc. | $9M | |
| GLUC Glucose Health, Inc. | $9M | |
| BON Bon Natural Life Ltd | $7M | |
| NAII Natural Alternatives International Inc | $7M | |
| PLSH Panacea Life Sciences Holdings, Inc. | $6M | |
| AIBT Aibotics, Inc. | $3M | |
| CYAN Cyanotech Corp | $3M | |
| IMCC Im Cannabis Corp. | $980K | |
| NPHC Nutra Pharma Corp | $720K | |
| MEHA Functional Brands Inc. | $140K | |
| NTRR Neutra Corp. | N/A | |
| SNYRQ Synergy Chc Corp. | N/A |
Canadian cannabis LP stocks are down across the board. Only Aurora Cannabis and Cronos reported net income recently. SNDL and Tilray still dominate the group in terms of highest revenues. Each company ...
SNDL INC (SNDL) delivered earnings and revenue surprises of -50.00% and +2.49%, respectively, for the quarter ended September ...
On Tuesday, SNDL Inc. SNDL reported mixed third-quarter 2026 results. Although sales beat the Zacks Consensus Estimate, ...
Our AI scores Sndl Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
For SNDL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -21.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 4.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Sndl Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
30 issuers in our coverage, SNDL included, share the SEC industry code Medicinal Chemicals & Botanical Products. The largest are: Definium Therapeutics, Inc. (DFTX), Trulieve Cannabis Corp. (TRLV), Cronos Group Inc. (CRON), Tilray Brands, Inc. (TLRY), Aurora Cannabis Inc (ACB), Canopy Growth Corp (CGC).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.
